Leerink Partners Sticks to Their Hold Rating for CureVac (CVAC)
Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...
CureVac: Strong Financial Position and Promising Pipeline Justify Buy Rating
Analyst Roy Buchanan of JMP Securities reiterated a Buy rating on CureVac (CVAC – Research Report), retaining the price target of $16.00.
Brain Implant Startups Aim to Bring Vision Back to The Blind
Food and Drug Administration’s blessing to fast-track its vision technology, called Blindsight, through the regulatory ...
Ophthalmic Imaging Equipment Pipeline Market Research 2024: Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies
The "Ophthalmic Imaging Equipment Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update" report has been added to ...